Skip to main content
Equibles
LGVN logo

LGVN · Longeveron Inc. · Documents

Track LGVN — free

Use LGVN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LGVN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.81 +0.10 (+5.85%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have prepared a cash flow forecast which indicates that we do not have sufficient cash to meet our minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore we need to raise additional funds to continue as a going concern. As a result, there is substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$5.77M
Shares
3.19M
Volume · Nov 6 38.84K Avg daily vol (51 sessions) 114.41K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.2M down 49.9% 10-K filed Mar 17, 2026 Quarterly report FY2026 Q2 Revenue $287K down 9.2% 10-Q filed Aug 12, 2026 Latest results Financial results 8-K filed Aug 12, 2026 Earnings call Q2 2026 earnings call Held Aug 12, 2026
2026
Oct 26
Current report 8-K
Other events

Longeveron Inc. reported that laromestrocel did not meet ELPIS II’s primary efficacy endpoint, but achieved statistically significant MACE results of 8 events with standard of care versus 1 with laromestrocel (P=0.043); the company plans an FDA meeting.

Oct 14
Current report 8-K Events of Oct 7
Director or officer change, or executive pay

Longeveron Inc. announced that Dr. Nataliya Agafonova decided to step down as Chief Medical Officer, effective October 14, 2026, after notifying management on October 7, 2026.

Sep 23
Current report 8-K Events of Sep 16
Other events

Longeveron said ELPIS II in 40 infants with HLHS missed its primary efficacy endpoint: the intent-to-treat RVEF difference was −0.7 percentage points at Month 12 (95% CI: −7.3 to 5.9; p=0.8336). It began reviewing all options to maximize shareholder value.

Sep 14
Current report 8-K Events of Sep 11
Other events AI summary on its way
Aug 12
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $287K ▼ 9.2% Net loss $6.07M Diluted EPS -$0.19
Jul 29
Current report 8-K Events of Jul 24
Other events AI summary on its way
May 20
Proxy statement DEF 14A Meeting Jul 1, 2026
Proxy statement AI summary on its way
May 13
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $398K ▲ 4.5% Net loss $4.74M Diluted EPS -$0.19
May 8
Current report 8-K
Other events AI summary on its way
Mar 24
Current report 8-K Events of Mar 23
Other events AI summary on its way
Mar 17
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $1.2M ▼ 49.9% Net loss $22.7M Diluted EPS -$1.29
2025
Showing 1–50 of 191 documents
Key facts CIK 1721484 CUSIP 54303L302 13F (30d) 7 filings 4 filers Visit website Investor relations